drugset / Trial / NCT02453477

Gene Therapy for Transfusion Dependent Beta-thalassemia

NCT02453477 ↗

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a phase I/II study evaluating safety and efficacy of autologous hematopoietic stem cells genetically modified with GLOBE lentiviral vector encoding for the human beta-globin gene for the treatment of patients affected by transfusion dependent beta-thalassemia

Timeline

Start
2015-05
Primary completion
2019-08
Completion
2019-08

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Autologous hematopoietic stem cells genetically modified with GLOBE lentiviral vector encoding for the human beta-globin gene Unknown 5e+06 cells/kg Intramuscular

Indications